Needham upgraded Amicus (FOLD) to Buy from Hold with a $14 price target
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FOLD:
- Positive Outlook for Amicus Therapeutics Amid Legal Developments and Patent Confidence
- Jefferies says Galafold summary judgment as expected, may facilitate settlement
- Amicus presents four-year data from PROPEL study of Pombiliti, Opfolda
- Amicus Therapeutics’ Pompe Disease Study: A Potential Game-Changer for Investors
- Amicus Therapeutics’ Global Study on Pompe Disease: A Potential Game-Changer